paracelsius
Bluelighter
- Joined
- Mar 11, 2020
- Messages
- 197
Quite interesting Belgium-Dutch and Chinese studies:
Independently, this Chinese study also identified Chloroquine and Loperamide as potent anti-SARS-cov compounds in a screen of ~2000 approved drugs, confirming the Dutch study:
Chloroquine is all over headlines news as being studied for COVID-19. Loperamide, an OTC antidiarrheal is as potent as chloroquine in the same in vitro assays: Its EC50 to block virus replication (SARS-cov) is about 5.9microM, in the same range as that of chloroquine (4.1microM). However, for Loperamide, the EC50 is well above the plasma concentration reached for a NORMAL maximum daily dose recommended (16mg) in humans to treat diarrhea (NOT FOR ITS CENTRAL OPIOID ACTION): Lope plasma concentration is roughly 50x lower than the antiviral EC50 reported by these authors. On the other hand, Chloroquine recommended dose (up to 500mg) and plasma concentration is within range of its antiviral EC50; but it is also within range of its lethal dose LD50!
Now, my question is: since lope is abused by some opiates users (100s mg/daily?!! way above its antiviral EC50), does that make them unwknowingly protecting themselves from SARS-COVID-19 infection? Would be interesting to see if heavy lope users get sick from COVID-19 or if they do, how do they handle the course of the infection?
NB: Please note, these are CELL CULTURE IN VITRO assays (doesn't mean Loperamide would work in vivo). Just like the jury is still out for Chloroquine (the real Scientific Jury not the "Know-it-all" "Doctor-in-Chief" claiming: "It works because I say so!!!"). I am just pointing out a potential alternative to Chloroquine to study for COVID-19 therapeutics, which incidentally turns out to be an abused...over-the-counter OPIOID!
de Wilde A, Jochmans D, Posthuma CC. et al. Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture. Antimicro Agents Chemother.2014; 58 ( 8 ): 4874-4884.
Abstract:..Registered therapeutics for the treatment of coronavirus infections are not avail able. Moreover, the pace of drug development and registration for human use is generally incompatible with strategies to combat emerging infectious diseases. Therefore, we have screened a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. If such compounds proved sufficiently potent, their efficacy might be directly assessed in MERS patients. We identified four compounds (chloroquine, chlorpromazine, loperamide, and lopinavir) inhibiting MERS-CoV replication in the low micromolar range (50% effective concentrations [EC50s], 3 to 8 microM). Moreover, these compounds also inhibit the replication of SARS coronavirus and human coronavirus 229E. Although their protective activity (alone or in combination) remains to be assessed in animal models, our findings may offer a starting point for treatment of patients infected with zoonotic coronaviruses like MERS-CoV. Although they may not necessarily reduce viral replication to very low levels, a moderate viral load reduction may create a window during which to mount a protective immune response (cf txt for data on SARS-cov2 ie COVID-19).
Independently, this Chinese study also identified Chloroquine and Loperamide as potent anti-SARS-cov compounds in a screen of ~2000 approved drugs, confirming the Dutch study:
Shen L, Niu J,Wang C. et al High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses. J Virology. 2019; 93(12): e00023-19.
Chloroquine is all over headlines news as being studied for COVID-19. Loperamide, an OTC antidiarrheal is as potent as chloroquine in the same in vitro assays: Its EC50 to block virus replication (SARS-cov) is about 5.9microM, in the same range as that of chloroquine (4.1microM). However, for Loperamide, the EC50 is well above the plasma concentration reached for a NORMAL maximum daily dose recommended (16mg) in humans to treat diarrhea (NOT FOR ITS CENTRAL OPIOID ACTION): Lope plasma concentration is roughly 50x lower than the antiviral EC50 reported by these authors. On the other hand, Chloroquine recommended dose (up to 500mg) and plasma concentration is within range of its antiviral EC50; but it is also within range of its lethal dose LD50!
Now, my question is: since lope is abused by some opiates users (100s mg/daily?!! way above its antiviral EC50), does that make them unwknowingly protecting themselves from SARS-COVID-19 infection? Would be interesting to see if heavy lope users get sick from COVID-19 or if they do, how do they handle the course of the infection?
NB: Please note, these are CELL CULTURE IN VITRO assays (doesn't mean Loperamide would work in vivo). Just like the jury is still out for Chloroquine (the real Scientific Jury not the "Know-it-all" "Doctor-in-Chief" claiming: "It works because I say so!!!"). I am just pointing out a potential alternative to Chloroquine to study for COVID-19 therapeutics, which incidentally turns out to be an abused...over-the-counter OPIOID!